Evoniks, Standalone

Evonik's Standalone Story Hinges on Whether 40% Growth Can Survive the Loss of Middle East Tailwinds

Published on 11/21/2026 at 13:11 | Editorial boerse-global.de
Evonik's Q3 adjusted EBITDA rose 40% to EUR 629 million, but with BASF's takeover bid withdrawn, focus shifts to standalone 2027 earnings.
Evoniks, Standalone, Story, Hinges, Whether, Growth, Can, Survive, Loss, Middle Illustration mit AI erstellt.

Evonik's third-quarter figures landed with force: adjusted EBITDA for Q3 2026 jumped 40% year-on-year to EUR 629 million. For anyone holding the stock, the immediate question is how much of that surge carries into next year — and that question now matters more than ever, because the takeover premium that once sat beneath the share price has evaporated.

BASF walked away from its pursuit on Thursday, and with it went the floor that its indicative cash offers had provided. Evonik had turned down two non-binding all-cash proposals, the last pitched at EUR 24 per share, valuing the specialty chemicals group at roughly EUR 11.18 billion. BASF had weighed a modest increase but never tabled a fresh bid. Shares closed at EUR 18.18 yesterday, well below that final approach.

Interim CEO Claus Rettig was blunt about the path forward: the company will push ahead at full tilt with its standalone development. That shifts the valuation debate squarely onto one terrain — how much operating profit Evonik can generate on its own.

A Shareholder's Patience, and a Political Hurdle

Not everyone was cheering BASF's exit. The RAG-Stiftung, Evonik's largest investor with a 43% stake, would have preferred the suitor to show more staying power, according to the Rhein-Neckar-Zeitung. That regret is not an endorsement of the last offer — it reflects the foundation's reliance on Evonik dividends, which make the company's payout capacity a live concern alongside its growth prospects.

Politics played its part too. The Frankfurter Allgemeine Zeitung points to resistance in North Rhine-Westphalia as a decisive factor in the deal's collapse. Ministerpräsident Hendrik Wüst flagged the 11,000 Evonik jobs in the state — and he also sits on the RAG-Stiftung's board of trustees. BASF had dangled possible commitments on German sites, research and employment through 2032.

Should investors sell immediately? Or is it worth buying Evonik?

Access to the books proved another stumbling block. By BASF's own account, Evonik's board was unwilling to open up for deeper due diligence. CEO Markus Kamieth argued a combination could have forged a stronger chemicals player, but he did not see a higher price as justified given Evonik's standalone prospects and risks.

The Number That Matters Now

Evonik's own guidance for full-year 2026 points to adjusted EBITDA in the upper half of a EUR 2.0–2.2 billion range. The crux for investors is how much of that earning power survives into 2027. Jefferies set a lower bar on 11 November, cutting its 2027 EBITDA forecast by 9%, citing the fading earnings cushion from supply disruptions in the Middle East. The broker now sees EBITDA below EUR 2 billion and downgraded the stock from Buy to Hold — even as it raised its price target from EUR 20 to EUR 21. The higher target does nothing to soften the fact that Jefferies has trimmed its operating expectations.

That frames a clean test: can Evonik offset the loss of that Middle East support elsewhere in the business? The brighter scenario requires the company to hold most of this year's earning power without the tailwind Jefferies describes. A sign of that would be 2027 adjusted EBITDA landing closer to Evonik's own current-year expectation than to the broker's reduced estimate — giving the valuation a firmer operating footing even without a takeover.

The gloomier path sees that support drain away with no offset, making the Q3 surge a poor yardstick for next year. Hitting the annual guidance would not dispel the risk: Evonik can meet this year's targets and still earn less the year after.

Lafayette as the Next Checkpoint

Tangible progress came on 10 November from Lafayette, Indiana, where Evonik produced its first GMP-grade batch of pharmaceutical lipids at its new Lipid Innovation Center. The first batch alone won't settle the standalone case — what counts is whether production advances translate into an earnings contribution. Full operation of the facility is targeted for mid-2027, a milestone that would mark a step beyond that initial quality batch.

Separately, the shareholder register is shifting. Reuters reported yesterday that the RAG-Stiftung reaffirmed plans to gradually reduce its stake from around 43% to 25.1% — an intention, not a completed sell-down. That overhang matters to investors, but it does not answer whether Evonik can defend its operating profit.

The stock's real measuring stick is whether adjusted EBITDA holds near this year's expected level despite weakening support, or slides toward Jefferies' lowered estimate. That distinction carries more weight than the price of a rejected bid.

Ad

Evonik Stock: New Analysis - 21 November

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...

Disclaimer...
en | DE000EVNK013 | EVONIKS | boerse | 70542603 |